GenSight BIOLOGICS

[redacted]

European Medecines Agency.
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Paris, April 20th 2023

Subject: Withdrawal of Marketing Authorization Application for LUMEVOQ® (INN : lenadogene nolparvovec) 1x10^{12} vg/ml suspension for intravitreal injection, EMEA/H/C/005047/0000)

Dear Dr Enzmann,

Dear Dr Reischl,

We would like to inform you that, at this point in time, GenSight Biologics SA (GenSight) has taken the decision to immediately withdraw the Marketing Authorization Application of LUMEVOQ® (INN : lenadogene nolparvovec) 1x10^{12} vg/ml suspension for intravitreal injection, which was intended to be used for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by a confirmed G11778A mutation in the ND4 mitochondrial gene.

This withdrawal is based on the CAT consideration that the extent of our clinical data would not lead the Committee to conclude on the efficacy of LUMEVOQ®.

GenSight thanks the Committee for the opportunity to respectfully explain its disagreement with the rapporteurs' assessment during the oral explanation of April 19. We deeply regret that the assessment did not evolve after this detailed presentation.

LUMEVOQ® is a gene therapy that specifically addresses ND4-LHON, a devastating blinding rare disease with high unmet need. GenSight would like to express its strong disappointment that the Committee did not consider at its value the body of evidence provided, consisting of a clinical package including three phase 3 studies (on 174 patients) and compassionate use experience both in Europe and US (on 63 patients), assembling an unprecedented overall data set on 252 patients in such a rare disease. In addition, GenSight has provided valid and demonstrative comparisons versus natural history of the disease and versus idebenone, which are all largely in favour of

LUMEVOQ®. We further note in this regard that idebenone has been registered in the indication under exceptional circumstances and based on limited data sets.

GenSight acknowledges that issues remain on the CMC part and is grateful that EMA granted extended clock stops in the previous steps of the procedure acknowledging the challenges faced during the COVID crisis period. GenSight has provided a clear plan to the Committee to support validation of the process and to address unresolved issues under a reasonable timeframe; other remaining issues are expected to be resolved when the comparability of batches is established.

GenSight reserves the right to make further submissions at a future date in this or other therapeutic indications.

GenSight is committed to ensure that European patients will access this therapeutic solution in the earliest possible timeframe.

GenSight would like to thank the rapporteurs and all assessors, the CAT, PRAC and CHMP members and EMA project leaders and personnels for the time dedicated to reviewing this application and the valuable support and guidance provided during the procedure. We will continue to interact with EMA for agreeing a regulatory path forward.

GenSight agrees for this letter to be published on the EMA website.

Yours sincerely,

[redacted]

[redacted]